drugset / Trial / NCT04528095

SMART Design to Compare Antipsychotic Treatments in Treatment-Resistant Schizophrenia

NCT04528095

Phase 3 Unknown 162 enrolled Shanghai Mental Health Center
RandomizedSequentialSingle-blindTreatment

Summary

The project intends to take treatment-resistant schizophrenia as the research object and uses sequential multiple assignment randomized trial(SMART) design to define the treatment recommendations of different drug regimen for treatment resistant schizophrenia and to determine the physical enhancement regimen for clozapine-resistant schizophrenia and to explore targeted regulation scheme for ultra-resistant schizophrenia.

Timeline

Start
2020-12
Primary completion
2022-12
Completion
2022-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Amisulpride Small molecule 200 mg
Subject Amisulpride Small molecule 800 mg
Subject Clozapine Other / unclassified 400 mg
Subject Clozapine Other / unclassified 600 mg
Subject Gingke biloba Unknown 120 mg
Subject Gingke biloba Unknown 360 mg

Indications